Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
pharmaceutical investing Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Seegnal's operating subsidiary Seegnal E-Health Ltd. hires AI VP to Strengthen AI Capabilities and Accelerates Development of Seegnal Guard
